PKM and cancer: Interestingly, CB-PIC significantly abrogated the expresion of a glycolytic enzyme pyruvate kinase M2 (PKM2) in HepG2 cells more than in LNCaP, A549, and HCT-116 cells, implying the susceptibility of HepG2 cells to CB-PIC rather than other cancer cells.